°øÁö : µµÄìÁõ±Ç°Å·¡¼Ò JASDAQ ½ºÅÄ´Ùµå ½ÃÀå ½Å±Ô »óÀå °ü·Ã ¾È³»

Global Information
ȸ»ç¼Ò°³ | ¹®ÀÇ | ºñ±³¸®½ºÆ®

¼¼°èÀÇ ¿ø·áÀǾàǰ(API) ½ÃÀå

¸®¼­Ä¡»ç BCC Research
¹ßÇàÀÏ ¹ßÇ࿹Á¤ »óǰ ÄÚµå 980079
ÆäÀÌÁö Á¤º¸ ¿µ¹® 148 Pages
°¡°Ý
US $ 5,500 £Ü 6,122,000 PDF (Single User License) help
1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº Copy & Paste°¡ °¡´ÉÇÕ´Ï´Ù. Àμâ±â´É¿¡ Á¦¾àÀº ¾øÀ¸³ª ¿øÄ¢ÀûÀ¸·Î Çã¿ëµÈ ÀμâȽ¼ö´Â 1ȸÀ̸ç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿¡ ÁØÇÕ´Ï´Ù.
US $ 6,600 £Ü 7,346,000 PDF (2-5 Users) help
µ¿ÀÏ »ç¾÷Àå ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº Copy & Paste°¡ °¡´ÉÇÕ´Ï´Ù. Àμâ±â´É¿¡ Á¦¾àÀº ¾øÀ¸³ª ¿øÄ¢ÀûÀ¸·Î Çã¿ëµÈ ÀμâȽ¼ö´Â 5ȸ±îÁöÀ̸ç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿¡ ÁØÇÕ´Ï´Ù.
US $ 7,920 £Ü 8,815,000 PDF (Site License) help
µ¿ÀÏ »ç¾÷Àå ³» ¸ðµç ºÐµéÀÌ °øÀ¯ÇÏ¿© ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº Copy & Paste°¡ °¡´ÉÇÕ´Ï´Ù. ÀμâȽ¼ö¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿¡ ÁØÇÕ´Ï´Ù.
US $ 9,504 £Ü 10,578,000 PDF (Enterprise License) help
µ¿ÀÏ ±â¾÷ ³» ¸ðµç ºÐµéÀÌ °øÀ¯ÇÏ¿© ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº Copy & Paste°¡ °¡´ÉÇÕ´Ï´Ù. ÀμâȽ¼ö¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿¡ ÁØÇÕ´Ï´Ù.


¼¼°èÀÇ ¿ø·áÀǾàǰ(API) ½ÃÀå
¹ßÇàÀÏ : ¹ßÇ࿹Á¤ ÆäÀÌÁö Á¤º¸ : ¿µ¹® 148 Pages

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹®¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¿ø·áÀǾàǰ(API) ½ÃÀå ±Ô¸ð´Â ¿¹Ãø±â°£ Áß 5.1%ÀÇ CAGR·Î È®´ëµÇ°í, 2020³â 1,354¾ï ´Þ·¯¿¡¼­ 2025³â¿¡´Â 1,733¾ï ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Á¦Á¶ ºÎ¹®º°·Î º¸¸é »ç³» Á¦Á¶ ºÎ¹®ÀÌ ±â°£ Áß 4.8%·Î È®´ëµÇ°í, 2020³â 529¾ï ´Þ·¯¿¡¼­ 2025³â¿¡´Â 670¾ï ´Þ·¯·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ¶ÇÇÑ CMO ºÎ¹®Àº 5.7%ÀÇ CAGR·Î È®´ëµÇ°í, 2020³â 387¾ï ´Þ·¯¿¡¼­ 2025³â¿¡´Â 511¾ï ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¿ø·áÀǾàǰ(API : Active Pharmaceutical Ingredients) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå Á¤ÀÇ¿Í °³¿ä, ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19) ¹× ±âŸ ½ÃÀå ¿µÇâ¿äÀÎ ºÐ¼®, ±ÔÁ¦ »óȲ, ±â¼ú¡¤Á¦Á¶ µ¿Çâ, ½ÃÀå ±Ô¸ð ÃßÁ¤°ú ¿¹Ãø, Á¦Á¶¾÷ü¿Í ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ±¸ºÐ¡¤ÃÖÁ¾»ç¿ë¡¤¿ø·á¡¤ºÐÀÚ Á¾·ù¡¤Áö¿ª/ÁÖ¿ä ±¹°¡ µî °¢Á¾ ¼¼ºÐÈ­º° ³»¿ª, °æÀï »óȲ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀ» Á¤¸®Çß½À´Ï´Ù.

Á¦1Àå ¼­·Ð

Á¦2Àå ¿ä¾à°ú ÇÏÀ̶óÀÌÆ®

Á¦3Àå ¼­·Ð

  • Á¦¾à »ê¾÷ °³¿ä
  • ÀǾàǰ ½ÃÀå¿¡ ´ëÇÑ Æ¯Çã ¸¸·áÀÇ ¿µÇâ
  • ÀǾàǰ °³¹ßÀÇ º¯È­
  • Drug Discovery & Development ÇÁ·Î¼¼½º
  • Ÿ°Ù ¼±Á¤ ¹× °ËÁõ
  • Drug Discovery¿ë ±â¼ú
  • Á¦¾à ºñÁö´Ï½º ¸ðµ¨
  • ½ÃÀå ¿ªÇÐ : ÀǾàǰ
  • ÀǾàǰ °³¹ß ºñ¿ë
  • ¼¼°èÀÇ ÀǾàǰ °ø±Þ¸Á
  • API Á¤ÀÇ
  • API ¿ø·á
  • API Á¦Á¶ ¹æ¹ý
  • API Á¦Á¶ : ÇÕ¼º ·çÆ®
  • Á¦Á¶ ¹æ¹ý
  • ¿ø·áÀǾàǰ ½ÃÀå
  • ½ÃÀå ¿ªÇÐ
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • »õ·Î¿î µ¿Çâ
  • API »ý»ê°ú °ø±Þ¸Á¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ
  • API °¡°Ý µ¿Çâ : COVID-19ÀÇ ¿µÇâ
  • Porter's Five Forces ºÐ¼®
  • ±ÔÁ¦ »óȲ

Á¦4Àå ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Á¦Á¶¾÷ü¡¤¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õº°

  • ÀÚ»ç¿ë
  • ÆÇ¸Å¿ë
  • CMO
    • °³¿ä
    • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø

Á¦5Àå ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëº°

  • ÀÓ»ó½ÃÇè
  • »ó¿ë
    • °³¿ä
    • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ¿ø·áº°

  • ÀÚ¿¬ À¯·¡
    • ½Ä¹° À¯·¡
    • µ¿¹° À¯·¡
    • ±âŸ
      • °³¿ä
      • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
  • ÇÕ¼º API
    • È­ÇÐ ÇÕ¼º
    • »ýü Ã˸Å
    • ¼¼Æ÷ ¹è¾ç¹ý
      • °³¿ä
      • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø

Á¦7Àå ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ºÐÀÚ Á¾·ùº°

  • ¼ÒºÐÀÚ
    • ºê·£µåÈ­ API
    • ¹ü¿ë API
      • °³¿ä
      • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
  • »ý¹°Á¦Á¦
    • Åé ¼¿¸µ »ý¹°Á¦Á¦
    • ºê·£µåÈ­ API
    • ¹ÙÀÌ¿À½Ã¹Ð·¯ API
      • °³¿ä
      • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø

Á¦8Àå ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Áö¿ª¡¤ÁÖ¿ä ±¹°¡º°

  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ±âŸ Áö¿ª
    • °³¿ä
    • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ±¹°¡º°

Á¦9Àå °ø±Þ¾÷ü »óȲ°ú ÁÖ¿ä Àü°³

  • °ø±Þ¾÷ü »óȲ
  • ÀÚ»ç¿ë Á¦Á¶¾÷ü
  • »ó¿ë API Á¦Á¶¾÷ü
  • CMO/CDMO
  • API ´ÜÆíÈ­
  • ÃÖ±ÙÀÇ Àü°³¡¤ÅõÀÚ È°µ¿
  • COVID-19ÀÇ ¿µÇâ

Á¦10Àå ±â¾÷ °³¿ä

  • ABBVIE CONTRACT MANUFACTURING
  • AESICA PHARMACEUTICALS LTD.
  • AUROBINDO PHARMA
  • ACTAVIS PLC
  • ALBANY MOLECULAR RESEARCH INC.(AMRI)
  • AVID BIOSERVICES INC.
  • BASF AG
  • BOEHRINGER INGELHEIM
  • CAMBREX CORP.
  • CIPLA
  • CSPC PHARMACEUTICAL GROUP
  • CORDEN PHARMA INTERNATIONAL GMBH
  • DISHMAN GROUP
  • DIVIS LABORATORIES LTD.
  • DR REDDY'S LABORATORY
  • FAREVA GROUP
  • GLAXOSMITHKLINE PLC
  • HALO PHARMA
  • HETERO
  • JOHNSON MATTHEY PHARMACEUTICAL MATERIALS INC.
  • JUBILANT LIFE SCIENCES LTD.
  • LONZA
  • LUPIN
  • MERCK KGAA
  • MYLAN N.V.
  • NOVARTIS AG
  • PATHEON
  • PFIZER CENTREONE
  • PIRAMAL PHARMA SOLUTIONS
  • SHANDONG XINHUA PHARMACEUTICAL CO. LTD.
  • SIEGFRIED AG
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES, INC.
  • WUXI APPTEC
  • ZHEJIANG CHEMICALS IMPORT/EXPORT CORP.
  • ZHUHAI UNITED LABORATORIES CO. LTD.

Á¦11Àå ºÎ·Ï : ¾à¾î

KSM

List of Tables

  • Summary Table : Global Market for Active Pharmaceutical Ingredients (APIs), by Manufacturer Type, Through 2025
  • Table 1 : Average Cost of Drug Development, by Stage, 2018
  • Table 2 : Advantages and Disadvantages of Using Natural APIs
  • Table 3 : Advantages and Disadvantages of Using Synthetic APIs
  • Table 4 : Most Significant PE Deals in India Pharma, 2020
  • Table 5 : API Manufacturers: Manufacturing Facility Expansion
  • Table 6 : List of Key APIs and their Price Hikes, January 2020-April 2020
  • Table 7 : Regulatory Requirements of GMP and Supply Chain Integrity for APIs
  • Table 8 : Global Market for APIs, by Manufacturer Type, Through 2025
  • Table 9 : Global Market for Captive APIs, by Region, Through 2025
  • Table 10 : Global Market for Merchant APIs, by Region, Through 2025
  • Table 11 : Global Market for CMO APIs, by Region, Through 2025
  • Table 12 : Global Market for APIs, by End Use, Through 2025
  • Table 13 : Global Market for Clinical Trial APIs, by Region, Through 2025
  • Table 14 : Global Market for Commercial APIs, by Region, Through 2025
  • Table 15 : Global Market for APIs, by Origin, Through 2025
  • Table 16 : Global Market for Natural APIs, by Region, Through 2025
  • Table 17 : Global Market for Synthetic APIs, by Origin, Through 2025
  • Table 18 : Advantages and Disadvantages of the Biocatalytic Process
  • Table 19 : Cell Culture Types: Attributes and Applications
  • Table 20 : Global Market for APIs, by Molecule Type, Through 2025
  • Table 21 : Characteristics of Small Molecules
  • Table 22 : Global Market for Small Molecule APIs, by Region, Through 2025
  • Table 23 : Global Market for Small Molecule APIs, by Type, Through 2025
  • Table 24 : Global Market for Branded Small Molecule APIs, by Region, Through 2025
  • Table 25 : Global Market for Generic Small Molecule APIs, by Region, Through 2025
  • Table 26 : Characteristics of Large Molecules/Biologics
  • Table 27 : Global Market for Large Molecule APIs, by Region, Through 2025
  • Table 28 : Global Market for Large Molecule APIs, by Type, Through 2025
  • Table 29 : Global Market for Branded Biologic APIs, by Region, Through 2025
  • Table 30 : Global Market for Biosimilar APIs, by Region, Through 2025
  • Table 31 : Global Market for APIs, by Region, Through 2025
  • Table 32 : Medical Countermeasure (MCM) Drug Manufacturing Sites, 2020
  • Table 33 : North American Market for APIs, by Country, Through 2025
  • Table 34 : European Market for APIs, by Country, Through 2025
  • Table 35 : Asia-Pacific Market for APIs, by Country, Through 2025
  • Table 36 : RoW Market for APIs, by Country, Through 2025
  • Table 37 : Key API Manufacturers
  • Table 38 : Key India API Pharma Stocks with Varying Degree of Dependency on China for API Materials
  • Table 39 : Key Indian API Pharma Stock Gains Since February 2020
  • Table 40 : Aurobindo Pharma: Products and Services
  • Table 41 : AMRI: Manufacturing Facilities
  • Table 42 : AMRI: Products and Services
  • Table 43 : BASFAG: Products and Services
  • Table 44 : Cambrex Corp.: Manufacturing Facilities
  • Table 45 : Cambrex Corp.: Products and Services
  • Table 46 : Cordon Pharma International GmbH: Manufacturing Facilities
  • Table 47 : Cordon Pharma International GmbH: Products and Services
  • Table 48 : Dishman Group: Manufacturing Facilities
  • Table 49 : Dishman Group: Products and Services
  • Table 50 : Dr Reddy's Laboratory: Manufacturing Facilities
  • Table 51 : Halo Pharma: Capabilities
  • Table 52 : Lonza: Products and Services
  • Table 53 : Mylan N.V.: Products and Services
  • Table 54 : Siegfried AG: Products and Services
  • Table 55 : Sun Pharmaceutical Industries Ltd.: Products and Services
  • Table 56 : Teva Pharmaceutical Industries, Ltd.: Manufacturing Facilities
  • Table 57 : Teva Pharmaceutical Industries, Ltd.: Products and Services
  • Table 58 : Abbreviations Used in this Report

List of Figures

  • Summary Figure : Global Market for Active Pharmaceutical Ingredients (APIs), by Manufacturer Type, 2018-2025
  • Figure 1 : Drug Development, by Phase
  • Figure 2 : End-to-End Pharmaceutical Supply Chain
  • Figure 3 : API Supply Chain
  • Figure 4 : Global API Supply Chain Network
  • Figure 5 : Chemical Synthetic Process
  • Figure 6 : Biological Process
  • Figure 7 : Natural Sources-Extraction Process
  • Figure 8 : Global Market for APIs, 2018-2025
  • Figure 9 : Active Pharmaceutical Ingredients: Market Dynamics
  • Figure 10 : Survey on Impact of COVID-19 on the Pharma Supply Chain, 2020
  • Figure 11 : Impact of COVID-19 on Pharma Supply Chain
  • Figure 12 : Supply Chain Disruption in the Pharmaceutical Value Chain
  • Figure 13 : Key Antibiotic API Price Hikes, January 2020-April 2020
  • Figure 14 : Price Hikes for Key Antimalarial & Antiviral APIs, January 2020-April 2020
  • Figure 15 : Price Hikes for Key Pain & Anti-inflammatory APIs, January 2020-April 2020
  • Figure 16 : Price Hikes for Key Vitamin APIs, January 2020-April 2020
  • Figure 17 : FDA cGMP Manufacturing Guidance Documents
  • Figure 18 : FDA Site Inspections and Possible Actions
  • Figure 19 : European cGMP Guidelines Documentation
  • Figure 20 : European Site Inspection Outcomes
  • Figure 21 : Global Market for APIs, by Manufacturer Type, 2018-2025
  • Figure 22 : Global Market for Captive APIs, by Region, 2018-2025
  • Figure 23 : Global Market for Merchant APIs, by Region, 2018-2025
  • Figure 24 : Global Market for CMO APIs, by Region, 2018-2025
  • Figure 25 : API Production Flow: From Clinical Development to Large Scale Manufacture
  • Figure 26 : Mortality Rates of Selected Disease, 2020
  • Figure 27 : Global Market for Clinical Trial APIs, by Region, 2018-2025
  • Figure 28 : Global Market for Commercial APIs, by Region, 2018-2025
  • Figure 29 : Global Market for Natural APIs, by Region, 2018-2025
  • Figure 30 : Global Market for Synthetic APIs, by Region, 2018-2025
  • Figure 31 : Global Market for Synthetic APIs, by Origin, 2018-2025
  • Figure 32 : Global Market for Small Molecule APIs, by Type, 2018-2025
  • Figure 33 : Global Market for Branded Small Molecule APIs, by Region, 2018-2025
  • Figure 34 : Global Market for Generic Small Molecule APIs, by Region, 2018-2025
  • Figure 35 : Global Market for Large Molecule APIs, by Region, 2018-2025
  • Figure 36 : Global Market for Large Molecule APIs, by Type, 2018-2025
  • Figure 37 : Global Market for Branded Biologic APIs, by Region, 2018-2025
  • Figure 38 : Global Market for Biosimilar APIs, by Region, 2018-2025
  • Figure 39 : Global Market for APIs, by Region, 2018-2025
  • Figure 40 : North American Market for APIs, by Country, 2018-2025
  • Figure 41 : European Market for APIs, by Country, 2018-2025
  • Figure 42 : Asia-Pacific Market for APIs, by Country, 2018-2025
  • Figure 43 : RoW Market for APIs, by Country, 2018-2025

Highlights:

The global market for active pharmaceutical ingredients (APIs) should grow from $135.4 billion in 2020 to $173.3 billion by 2025, at compound annual growth rate (CAGR) of 5.1% for the period of 2020-2025.

The captive segment market for active pharmaceutical ingredients (APIs) should grow from $52.9 billion in 2020 to $67.0 billion by 2025, at a CAGR of 4.8% for the period of 2020-2025.

The CMO segment market for active pharmaceutical ingredients (APIs) should grow from $38.7 billion in 2020 to $51.1 billion by 2025, at a CAGR of 5.7% for the period of 2020-2025.

Report Scope:

This report is an overview of the pharmaceutical industry landscape and active pharmaceutical ingredients (API), along with the current trends and dynamics shaping the API market landscape. API sourcing trends and regulatory guidelines that impact the procurement of APIs are studied here. The increasing importance of outsourced API manufacturing activities and the impact on the pharmaceutical industry are covered in the report.

In this report, the API market is segmented into molecular entity, manufacturer type, end use, and region. Further, it is segmented into two molecular entity groups: natural and synthetic API. Synthetic APIs are further segmented into chemical synthesis, biocatalytic and cell culture. Under the category of molecular entity, APIs are segmented into small molecules and large molecules. By sourcing type, the market is segmented into the captive market, merchant market and contract manufacturing organization (CMO). In terms of end use, the market is segmented into clinical trial use and commercial use.

In terms of geography, this report analyzes the market by the following regions: North America, Europe, Asia-Pacific, and Rest of the World (Latin America and the Middle East). The API market is very fragmented. Therefore, attempts have been made to present the market share held by selected companies.

Report Includes:

  • 27 data tables and 32 additional tables
  • An overview of the global active pharmaceutical ingredients (API) market
  • Estimation of the market size and analyses of market trends, with data from 2018, 2019, estimates for 2020 and projection of CAGR through 2025
  • Highlights of quantitative and qualitative data of the API market by molecular entity, manufacturer type, origin, end use and region
  • Detailed description of API sources, production methods, route of synthesis, and contract manufacturing organizations
  • Information on regulatory perspective on production methods of API and discussion on harmonization of API GMP standards and supply chain integrity
  • Impact analysis of coronavirus on the global economy; and discussion on impact of COVID-19 on API industry
  • Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market trends, market size, market forecast, and technological advancements within the industry
  • Discussion on issues like patent expiry and its impact on the pharmaceutical market, and details of changes in pharmaceutical drug development
  • Coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
  • Company profiles of major players of the industry, including Actavis PLC, BASF AG, Cambrex Corp., GlaxoSmithKline PLC and Sun Pharmaceutical Industries Ltd.

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

  • Highlights

Chapter 3 Active Pharmaceutical Ingredients - Introduction

  • Pharmaceutical Industry Overview
  • Patent Expiry Impact on the Pharmaceutical Market
  • Changes in Pharmaceutical Drug Development
  • Drug Discovery and Development Process
  • Target Identification and Validation
  • Technologies for Drug Discovery
  • Pharmaceutical Business Model
  • Pharmaceutical Market Dynamics
  • The Cost of Drug Development
  • Global Pharmaceutical Supply Chain
  • API Defined
  • Sources of APIs
  • API Production Methods
  • API Production: Route of Synthesis
  • Production Methods
  • Active Pharmaceutical Ingredient Market
  • Market Dynamics
  • Market Drivers
  • Market Challenges
  • Emerging Trends
  • Impact of COVID on API Production and Supply Chain
  • API Pricing Trends and Increases Amidst COVID-19
  • Porter's Five-Force Analysis in the API Market
  • Threat of New Entrants
  • Threat of Substitute Products or Services
  • Bargaining Power of Customers (Buyers)
  • Bargaining Power of Suppliers
  • Intensity of Competitive Rivalry
  • Current State of Active Pharmaceutical Ingredient Regulations
  • Harmonization of API GMP Standards and Supply Chain Integrity
  • CMO/CDMO Regulations
  • Regulation in the U.S.
  • Regulation in Europe

Chapter 4 Active Pharmaceutical Ingredients Market by Manufacturer/ Service Provider

  • Introduction and Global Markets
  • The API Market by Manufacturer Type
  • Captive Market: Market Analysis
  • Overview
  • Market Size and Forecast
  • Merchant Market: Market Analysis
  • Overview
  • Market Size and Forecast
  • Contract Manufacturing Organizations (CMOs): Market Analysis
  • Overview
  • Market Size and Forecast

Chapter 5 Active Pharmaceutical Ingredients Market by End Use

  • Introduction and Global Markets
  • Clinical Trial: Market Analysis
  • Overview
  • Market Size and Forecast
  • Commercial: Market Analysis
  • Overview
  • Market Size and Forecast

Chapter 6 Active Pharmaceutical Ingredients by Origin

  • Introduction and Market Analysis
  • Natural Origin: Types and Market Analysis
  • Plant Sources
  • Animal Sources
  • Others
  • Market Size and Forecast
  • Synthetic APIs: Types and Market Analysis
  • Overview
  • Market Size and Forecast
  • Chemical Synthesis: Introduction and Market Analysis
  • Biocatalysis: Introduction and Market Analysis
  • Cell Culture Methods: Introduction and Market Analysis

Chapter 7 Active Pharmaceutical Ingredients Market by Molecule Type

  • Introduction and Global Markets
  • Small Molecules: Types and Market Analysis
  • Market Size and Forecast
  • Branded Small Molecule APIs
  • Generic APIs
  • Biologics: Types and Market Analysis
  • Top-Selling Biologics
  • Market Size and Forecast
  • Branded Biologic APIs
  • Biosimilar APIs

Chapter 8 Active Pharmaceutical Ingredients Market by Region

  • Introduction
  • North America
  • Overview
  • Market Size by Country
  • Europe
  • Overview
  • Market Size by Country
  • Asia-Pacific
  • Overview
  • API Production in Asia-Pacific
  • Market Size by Country
  • Rest of the World
  • Overview

Chapter 9 Supplier Landscape and Key Industry Developments

  • Supplier Landscape
  • Captive Manufacturers
  • Merchant API Manufacturers
  • CMOs/CDMOs
  • API Fragmentation: -Reasons for Fragmented Industry Structure
  • Recent Industry and Investment Activities
  • Impact of COVID-19 on API Manufacturers

Chapter 10 Company Profiles

  • ABBVIE CONTRACT MANUFACTURING
  • AESICA PHARMACEUTICALS LTD.
  • AUROBINDO PHARMA
  • ACTAVIS PLC
  • ALBANY MOLECULAR RESEARCH INC. (AMRI)
  • AVID BIOSERVICES INC.
  • BASF AG
  • BOEHRINGER INGELHEIM
  • CAMBREX CORP.
  • CIPLA
  • CSPC PHARMACEUTICAL GROUP
  • CORDEN PHARMA INTERNATIONAL GMBH
  • DISHMAN GROUP
  • DIVIS LABORATORIES LTD.
  • DR REDDY'S LABORATORY
  • FAREVA GROUP
  • GLAXOSMITHKLINE PLC
  • HALO PHARMA
  • HETERO
  • JOHNSON MATTHEY PHARMACEUTICAL MATERIALS INC.
  • JUBILANT LIFE SCIENCES LTD.
  • LONZA
  • LUPIN
  • MERCK KGAA
  • MYLAN N.V.
  • NOVARTIS AG
  • PATHEON
  • PFIZER CENTREONE
  • PIRAMAL PHARMA SOLUTIONS
  • SHANDONG XINHUA PHARMACEUTICAL CO. LTD.
  • SIEGFRIED AG
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES, INC.
  • WUXI APPTEC
  • ZHEJIANG CHEMICALS IMPORT/EXPORT CORP.
  • ZHUHAI UNITED LABORATORIES CO. LTD.

Chapter 11 Appendix: Abbreviations

  • Abbreviations
Back to Top
ÀüÈ­ ¹®ÀÇ
F A Q